Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXM Acxiom	$48.48	$48.48	$18.60 ▼ $51.51	N/A	N/A	867,905 shs	660,433 shs
BMY Bristol Myers Squibb	$46.73 -0.6%	$48.01	$39.35 ▼ $63.33	$95.71B	0.38	12.95 million shs	9.01 million shs
BRK.B Berkshire Hathaway	$486.37 -1.4%	$506.53	$403.82 ▼ $542.07	$1.06T	0.85	4.38 million shs	4.25 million shs
EFX Equifax	$258.31 -1.3%	$261.22	$199.98 ▼ $309.63	$32.52B	1.63	978,219 shs	606,956 shs
IPG Interpublic Group of Companies	$24.14 -2.2%	$24.23	$22.51 ▼ $33.05	$9.13B	1.06	5.77 million shs	9.25 million shs
PFE Pfizer	$24.29 -0.1%	$23.38	$20.92 ▼ $31.54	$138.21B	0.57	41.29 million shs	25.59 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXM Acxiom	0.00%	0.00%	0.00%	0.00%	0.00%
BMY Bristol Myers Squibb	+0.14%	-0.45%	+0.33%	-20.51%	+11.39%
BRK.B Berkshire Hathaway	+1.17%	+2.04%	-2.07%	-7.39%	+19.24%
EFX Equifax	+2.66%	+2.45%	-0.15%	+8.41%	+9.06%
IPG Interpublic Group of Companies	+0.97%	+7.40%	+2.95%	-6.71%	-16.24%
PFE Pfizer	+1.10%	+1.25%	+4.16%	-3.52%	-14.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACXM Acxiom	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BMY Bristol Myers Squibb	4.9469 of 5 stars	3.2	5.0	4.2	4.0	3.0	3.3	1.3
BRK.B Berkshire Hathaway	0.4793 of 5 stars	1.0	0.0	0.0	0.0	1.4	0.0	1.9
EFX Equifax	4.7839 of 5 stars	3.4	4.0	1.7	4.1	2.0	2.5	1.9
IPG Interpublic Group of Companies	4.7141 of 5 stars	3.2	3.0	4.2	2.8	2.5	1.7	1.9
PFE Pfizer	4.8713 of 5 stars	2.3	4.0	4.2	4.3	2.4	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXM Acxiom	0.00	N/A	N/A	N/A
BMY Bristol Myers Squibb	2.32	Hold	$58.00	24.12% Upside
BRK.B Berkshire Hathaway	2.00	Hold	$520.00	6.91% Upside
EFX Equifax	2.74	Moderate Buy	$294.94	14.18% Upside
IPG Interpublic Group of Companies	2.30	Hold	$32.72	35.55% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	20.08% Upside

Current Analyst Ratings Breakdown

Latest IPG, EFX, BMY, PFE, BRK.B, and ACXM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	IPG Interpublic Group of Companies	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$34.00 ➝ $27.50
6/23/2025	EFX Equifax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$300.00 ➝ $285.00
6/20/2025	EFX Equifax	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$295.00
6/18/2025	EFX Equifax	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$277.00 ➝ $295.00
6/18/2025	EFX Equifax	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$300.00
6/10/2025	EFX Equifax	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$295.00 ➝ $305.00
5/22/2025	EFX Equifax	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$277.00 ➝ $296.00
5/21/2025	EFX Equifax	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$288.00 ➝ $306.00
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXM Acxiom	N/A	N/A	N/A	N/A	N/A	N/A
BMY Bristol Myers Squibb	$47.64B	2.00	$5.86 per share	7.97	$8.08 per share	5.78
BRK.B Berkshire Hathaway	$371.43B	2.82	$27.87 per share	17.45	$302.19 per share	1.61
EFX Equifax	$5.68B	5.65	$12.99 per share	19.88	$38.84 per share	6.65
IPG Interpublic Group of Companies	$10.69B	0.83	$4.25 per share	5.68	$10.37 per share	2.33
PFE Pfizer	$62.46B	2.21	$4.41 per share	5.51	$15.62 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXM Acxiom	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.50	7.67	1.39	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
BRK.B Berkshire Hathaway	$89.00B	$37.52	12.96	24.39	3.39	21.79%	7.20%	4.01%	N/A
EFX Equifax	$604.10M	$4.89	52.82	26.04	2.53	10.68%	18.81%	7.60%	7/16/2025 (Estimated)
IPG Interpublic Group of Companies	$689.50M	$1.31	18.43	8.50	N/A	4.69%	27.21%	5.94%	7/23/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.60	8.02	0.87	12.62%	20.33%	8.53%	7/29/2025 (Estimated)

Latest IPG, EFX, BMY, PFE, BRK.B, and ACXM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	N/A	IPG Interpublic Group of Companies	$0.55	N/A	N/A	N/A	$2.15 billion	N/A
7/16/2025	Q2 2025	EFX Equifax	$1.91	N/A	N/A	N/A	$1.51 billion	N/A
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
4/24/2025	Q1 2025	IPG Interpublic Group of Companies	$0.30	$0.33	+$0.03	-$0.23	$1.98 billion	$2.00 billion
4/22/2025	Q1 2025	EFX Equifax	$1.45	$1.53	+$0.08	$1.06	$1.41 billion	$1.44 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXM Acxiom	N/A	N/A	N/A	N/A	N/A
BMY Bristol Myers Squibb	$2.48	5.31%	N/A	92.88%	17 Years
BRK.B Berkshire Hathaway	N/A	N/A	N/A	N/A	N/A
EFX Equifax	$2.00	0.77%	N/A	40.90%	1 Years
IPG Interpublic Group of Companies	$1.32	5.47%	N/A	100.76%	13 Years
PFE Pfizer	$1.72	7.08%	N/A	124.64%	16 Years

Latest IPG, EFX, BMY, PFE, BRK.B, and ACXM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%		7/25/2025	9/2/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/22/2025	IPG Interpublic Group of Companies	quarterly	$0.33	5.49%	6/2/2025	6/2/2025	6/16/2025
4/23/2025	EFX Equifax	quarterly	$0.50	0.8%	5/23/2025	5/23/2025	6/13/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXM Acxiom	N/A	N/A	N/A
BMY Bristol Myers Squibb	2.65	1.28	1.17
BRK.B Berkshire Hathaway	N/A	0.32	0.32
EFX Equifax	0.86	0.85	0.85
IPG Interpublic Group of Companies	0.80	1.07	1.07
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXM Acxiom	94.47%
BMY Bristol Myers Squibb	76.41%
BRK.B Berkshire Hathaway	39.25%
EFX Equifax	96.20%
IPG Interpublic Group of Companies	98.43%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ACXM Acxiom	3.54%
BMY Bristol Myers Squibb	0.09%
BRK.B Berkshire Hathaway	6.05%
EFX Equifax	1.40%
IPG Interpublic Group of Companies	0.42%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXM Acxiom	N/A	N/A	N/A	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
BRK.B Berkshire Hathaway	392,400	2.16 billion	2.03 billion	Optionable
EFX Equifax	14,700	124.20 million	122.46 million	Optionable
IPG Interpublic Group of Companies	53,300	369.73 million	368.18 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

IPG, EFX, BMY, PFE, BRK.B, and ACXM Headlines

Recent News About These Companies

Pfizer Inc. (NYSE:PFE) Announces Quarterly Dividend of $0.43

4 hours ago | marketbeat.com

Pfizer declares $0.43 dividend

5 hours ago | seekingalpha.com

Pfizer Declares Third-Quarter 2025 Dividend | PFE Stock News

5 hours ago | gurufocus.com

Pfizer (PFE) Announces Consistent Quarterly Dividend

5 hours ago | gurufocus.com

Pfizer Declares Third-Quarter 2025 Dividend

June 25 at 5:30 PM | businesswire.com

Don't Sleep On Pfizer: The Turnaround Is Just Getting Started

June 25 at 2:21 PM | seekingalpha.com

Pfizer’s Inclacumab Study: A Long-term Safety Evaluation for Sickle Cell Disease

June 25 at 12:38 PM | tipranks.com

Pfizer’s New Phase 1 Study: Exploring PF-07999415’s Potential

June 25 at 12:38 PM | tipranks.com

Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

June 25 at 12:31 PM | finance.yahoo.com

Alpine Bank Wealth Management Invests $873,000 in Pfizer Inc. (NYSE:PFE)

June 25 at 7:42 AM | marketbeat.com

HBK Sorce Advisory LLC Has $3.65 Million Holdings in Pfizer Inc. (NYSE:PFE)

June 25 at 7:34 AM | marketbeat.com

Boomers Are Snapping Up 4 Super-Safe Passive Income Stocks Under $30

June 25 at 7:14 AM | 247wallst.com

Corundum Group Inc. Grows Stake in Pfizer Inc. (NYSE:PFE)

June 25 at 7:12 AM | marketbeat.com

Daymark Wealth Partners LLC Reduces Position in Pfizer Inc. (NYSE:PFE)

June 25 at 6:37 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Acquired by Lecap Asset Management Ltd.

June 25 at 6:29 AM | marketbeat.com

Strategic Investment Advisors MI Sells 39,033 Shares of Pfizer Inc. (NYSE:PFE)

June 25 at 5:52 AM | marketbeat.com

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

June 24 at 6:46 PM | zacks.com

Pfizer’s Promising Phase 1B Trial for Multiple Myeloma: Key Insights for Investors

June 24 at 4:28 PM | msn.com

Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?

June 24 at 11:26 AM | zacks.com

My 5 Favorite Dirt Cheap Stocks to Buy Right Now

June 24 at 7:10 AM | fool.com

WoodTrust Financial Corp Sells 149,391 Shares of Pfizer Inc. (NYSE:PFE)

June 24 at 6:02 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPG, EFX, BMY, PFE, BRK.B, and ACXM Company Descriptions

Acxiom NASDAQ:ACXM

LiveRamp Holdings, Inc. operates as a global technology company. It is engaged in providing identity platform leveraged by brands and partners to deliver innovative products and exceptional experiences. The firm's identifyLink connects people, data and devices across the digital and physical world, powering the people-based marketing revolution and allowing consumers to safely connect with brands and products. The company was founded in 1969 and is headquartered in San Francisco, CA.

Bristol Myers Squibb NYSE:BMY

$46.73 -0.30 (-0.64%)

Closing price 03:59 PM Eastern

Extended Trading

$46.70 -0.02 (-0.05%)

As of 07:59 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Berkshire Hathaway NYSE:BRK.B

$486.37 -7.11 (-1.44%)

Closing price 03:59 PM Eastern

Extended Trading

$486.46 +0.09 (+0.02%)

As of 07:59 PM Eastern

Berkshire Hathaway Inc., through its subsidiaries, engages in the insurance, freight rail transportation, and utility businesses worldwide. The company provides property, casualty, life, accident, and health insurance and reinsurance; and operates railroad systems in North America. It also generates, transmits, stores, and distributes electricity from natural gas, coal, wind, solar, hydroelectric, nuclear, and geothermal sources; operates natural gas distribution and storage facilities, interstate pipelines, liquefied natural gas facilities, and compressor and meter stations; and holds interest in coal mining assets. In addition, the company manufactures boxed chocolates and other confectionery products; specialty chemicals, metal cutting tools, and components for aerospace and power generation applications; flooring products; insulation, roofing, and engineered products; building and engineered components; paints and coatings; and bricks and masonry products, as well as offers manufactured and site-built home construction, and related lending and financial services. Further, it provides recreational vehicles, apparel and footwear products, jewelry, and custom picture framing products, as well as alkaline batteries; castings, forgings, fasteners/fastener systems, aerostructures, and precision components; and cobalt, nickel, and titanium alloys. Additionally, the company distributes televisions and information; franchises and services quick service restaurants; distributes electronic components; and offers logistics services, grocery and foodservice distribution services, and professional aviation training and shared aircraft ownership programs. It also retails automobiles; furniture, bedding, and accessories; household appliances, electronics, and computers; jewelry, watches, crystal, china, stemware, flatware, gifts, and collectibles; kitchenware; and motorcycle clothing and equipment. The company was incorporated in 1998 and is headquartered in Omaha, Nebraska.

Equifax NYSE:EFX

$258.31 -3.50 (-1.34%)

Closing price 03:59 PM Eastern

Extended Trading

$256.36 -1.95 (-0.76%)

As of 07:44 PM Eastern

Equifax Inc. operates as a data, analytics, and technology company. The company operates through three segments: Workforce Solutions, U.S. Information Solutions (USIS), and International. The Workforce Solutions segment offers services that enables customers to verify income, employment, educational history, criminal justice data, healthcare professional licensure, and sanctions of people in the United States; and employer customers with services that assist them in complying with and automating payroll-related and human resource management processes throughout the entire cycle of the employment relationship. The USIS segment provides consumer and commercial information services, such as credit information and credit scoring, credit modeling and portfolio analytics, locate, fraud detection and prevention, identity verification, and other consulting services; mortgage services; financial marketing services; identity management services; and credit monitoring products. The International segment offers information service products, which include consumer and commercial services, such as credit and financial information, and credit scoring and modeling; and credit and other marketing products and services, as well as offers information, technology, and other services to support debt collections and recovery management. The company serves customers in financial services, mortgage, retail, telecommunications, utilities, automotive, brokerage, healthcare, and insurance industries, as well as government agencies. It operates in Argentina, Australia, Brazil, Canada, Chile, Costa Rica, Dominican Republic, Ecuador, El Salvador, Honduras, India, Ireland, Mexico, New Zealand, Paraguay, Peru, Portugal, Spain, the United Kingdom, Uruguay, and the United States. The company was founded in 1899 and is headquartered in Atlanta, Georgia.

Interpublic Group of Companies NYSE:IPG

$24.14 -0.55 (-2.23%)

Closing price 03:59 PM Eastern

Extended Trading

$24.12 -0.03 (-0.10%)

As of 04:39 PM Eastern

The Interpublic Group of Companies, Inc. provides advertising and marketing services worldwide. It operates in three segments: Media, Data & Engagement Solutions, Integrated Advertising & Creativity Led Solutions, and Specialized Communications & Experiential Solutions. The Media, Data & Engagement Solutions segment provides media and communications services, digital services and products, advertising and marketing technology, e-commerce services, data management and analytics, strategic consulting, and digital brand experience under the IPG Mediabrands, UM, Initiative, Kinesso, Acxiom, Huge, MRM, and R/GA brand names. The Integrated Advertising & Creativity Led Solutions segment offers advertising, corporate, and brand identity services; and strategic consulting under FCB, IPG Health, McCann Worldgroup, and MullenLowe Group brands. Specialized Communications & Experiential Solutions segment provides public relations and other specialized communications services, live events, sports and entertainment marketing, and strategic consulting under IPG DXTRA Health, The Weber Shandwick Collective, Golin, Jack Morton, Momentum, and Octagon brand names. The company was formerly known as McCann-Erickson Incorporated and changed its name to The Interpublic Group of Companies, Inc. in January 1961. The Interpublic Group of Companies, Inc. was founded in 1902 and is headquartered in New York, New York.

Pfizer NYSE:PFE

$24.29 -0.02 (-0.08%)

Closing price 03:59 PM Eastern

Extended Trading

$24.26 -0.02 (-0.10%)

As of 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPG, EFX, BMY, PFE, BRK.B, and ACXM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPG, EFX, BMY, PFE, BRK.B, and ACXM Earnings

Compare Dividends

Latest IPG, EFX, BMY, PFE, BRK.B, and ACXM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPG, EFX, BMY, PFE, BRK.B, and ACXM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPG, EFX, BMY, PFE, BRK.B, and ACXM Company Descriptions

Acxiom NASDAQ:ACXM

Bristol Myers Squibb NYSE:BMY

Berkshire Hathaway NYSE:BRK.B

Equifax NYSE:EFX

Interpublic Group of Companies NYSE:IPG

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools